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C.A. Nienaber*Division of Cardiology (CAN), University of Rostock, Rostock, GermanyAneurysm of the abdominal aorta represent a poten-
tially life-threatening scenario in an increasingly
important segment of our aging patient population.
With improved health care in general many patients
reach an advanced age despite severe cardiovascular,
hypertensive and/or pulmonary comorbidity and,
thus, buy time for abdominal aneurysm to enlarge to
critical diameter in order to qualify for open surgical or
endovascular treatment. While surgical resection and
interposition of abdominal aortic prosthesis from
Dacron or Gortex have long been considered standard
treatment (despite a well known peri-operative
mortality), endovascular strategies have evolved
over the last decade to the perception of an accepted
standard of care in patients considered too sick or too
old for open surgery; advanced technology, the ease of
use and the temptation of a fully percutaneous
procedure may have carried away the new breed of
‘endovascular surgeons’ to jump on the bandwagon,
propelled by the prospect to both avoid surgical risk
by use of a nonsurgical approach, and induce
reconstructive remodeling of the aneurysmatic aorta
by depressurization and complete exclusion of the
aneurysmal sac.
In this ambience of compassion, turf battle between
classic surgery and the ‘new bread’ and wishful
thinking, the EVAR study group has provided the
community with important revelations from random-
ized studies on treatment of a ‘moving target’ called
AAA, in the context of increasing patients’ age,
constantly refining technology and improving oper-
ator skills. While treatment of large AAA with EVAR
reduced 30-day mortality to 1.7 versus 4.7% with open
repair (p!0.009) on an intention-to-treat basis, theng author. C.A. Nienaber, MD, FACC, FESC, Division
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as a licence to continue evaluation of EVAR by use of
longer follow-up.1 After 4 years all-cause mortality did
not improve with EVAR versus open repair of AAA
despite an initial post-interventional benefit of EVAR;
midterm aneurysm-related mortality was 4% with
EVAR versus 7% with open repair, a differential
explained by the 3% higher mortality with open
repair.2 This marginal advantage (at the expense of a
costly surveillance program) is consistent with
DREAM results3 but lead the authors to sobering
conclusions that EVAR may offer no advantage with
respect to all-cause mortality and quality of life in
patients with AAAR5.5 cm fit for open surgery.2
Scores for measures of quality of life and sexual
functioning favoured EVAR only in the early post-
operative period but equalized after 6 months with
open repair, in parallel with a continued need for
reinterventions with EVAR. A closer look, however,
revealed that many late complications after successful
EVAR are of low prognostic impact such as endoleak
type 2 requiring reintervention in only 17 of 79 cases.
Severe complications such as graft rupture (nZ9),
graft migration (nZ12), endoleak type I (nZ27) and
graft thrombosis (nZ12) requiring reintervention in 37
of 60 cases, however, are likely to be attributed to
technical or procedural problems with the stent-graft
or unsuitable anatomy, again reminding the medical
community of the inherently immature nature of an
emerging technology; moreover, at least six different
makes of endovascular devices were used with
different levels of experience. Yet midterm results
and outlook with EVAR may even be more sobering in
the light of the outcome data of the EVAR-2 trial:4
Patients considered unfit for open repair of AAA did
not benefit from EVAR in terms of improved survival
than without an intervention and produced more
costs. By nature EVAR-2 patients were older with moreEur J Vasc Endovasc Surg 30, 339–340 (2005)
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C. A. Nienaber340comorbidity than EVAR-1 patients; thus, confounding
variables of prognosis turned out to be too strong and
rendered the potential peri-operative advantage of
EVAR irrelevant considering that only nine aneurysm-
related fatalities per 100 patient years occurred in the
control arm randomized to observation.
The data presented by the EVAR-trialists (both
EVAR-1 30 days and midterm outcomes and EVAR-2
in patients unfit for open surgery) are not just
sobering, but provocative and revealing at the same
time. In accordance with the DREAM studies2,5
EVAR-1 showed significant early survival benefit
after 30 days with endovascular repair due to reduced
peri-interventional risk, corroborating previous obser-
vational evidence.6–8 Although, early euphoria has
been severely dampened by midterm follow-up out-
comes, on second sight, careful analysis of random-
ized data provides highly valuable information:
(1) Health status comprising age, comorbidities and
prognostic confounders, turned out as the most
important denominator of individual prognosis and
to a lesser degree the non-surgical nature of EVAR
(which can be performed percutaneously in local
anaesthesia). Thus, assessment of the general status
of health in the elderly and sicker population and
serious attempts for improvement should precede
EVAR, such as cardiopulmonary work-up, potentially
including PCI and respiratory improvement as inte-
gral part of strategic planning. Under particular
condition it appears justified to say No to EVAR and
conservative care may even be more appropriate.
(2) The nature of complications requiring reinter-
ventions after EVAR is often related to technical
shortcomings with current generation devices or to
the use in nonsuitable anatomy. Physicians and
industry have to recognize those limitations and
develop both better devices and improved selection
algorithms for treatment with EVAR.
(3) Eventually, while the Endovascular Community
should always embrace the ‘Nihil nocere’ principle (a
classic in medicine and surgery) and avoid well-
intended, but harmful treatment, it should also realize
the ‘moving target’ nature of the problem. Some
patients considered unfit for surgery can possibly be
improved and find themselves in a lower risk category
and eventually fit for surgery or EVAR. EVAR
technology and interventional skills will constantly
improve with training and the short-term differential
to open surgery is likely to increase. More elderly
patients will express a personal preference for a less
traumatic procedure such as EVAR (if performed by an
expert) despite lack of a clear-cut midterm advantage,
and may accept surveillance and interventions during
follow-up. And finally, the higher costs for follow-upEur J Vasc Endovasc Surg Vol 30, October 2005imaging with EVAR could be dramatically reduced with
a smarter surveillance strategy based on clinical and
ultrasound interrogation, instead of serial CT or MRI.
All things considered, even though at midterm
EVAR may not improve AAA prognosis as compared
to classic surgery and result at present in a draw after
an early advantage, EVAR is here to stay; better
staging and selection of patients, constantly improving
technology7 and the expertise of centres of excellence
for aortic diseases will enhance matching a given
patient with one of a variety of therapeutic options
including EVAR or even conservative treatment. Thus,
despite all new technology it is still wise to adhere to
the old principles of responsible use of clinical
judgement and offer especially the growing segment
of old patients with multiple comorbidities a holistic
approach with intelligent use of prognosticating tools
and interdisciplinary cooperation. Whether the results
of the EVAR trials and the cautious voice of Jonathan
Michaels9 will halt the trend of increasing use of EVAR
over open surgery remains to be seen; it is certain,
however, that the randomized data from EVAR-1 and
EVAR-2 refocus the debate on natural history and
patient selection for a forward moving technology.References
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